Home / Health / ₹9 Crore Drug Now ₹2.5 Lakh for Rare Disease

₹9 Crore Drug Now ₹2.5 Lakh for Rare Disease

Summary

  • Seven children with AHDS to receive tiratricol free for one year.
  • Compounded drug costs ₹2.5 lakh yearly, down from ₹9 crore.
  • Initiative brought drug cost down via pharmaceutical compounding.
₹9 Crore Drug Now ₹2.5 Lakh for Rare Disease

Seven children in India diagnosed with the rare genetic disorder Allan-Herndon-Dudley syndrome (AHDS) are set to receive a year's supply of the medicine tiratricol free of cost starting November 30, 2026. This significant development drastically cuts the annual treatment expense from an estimated ₹9 crore down to ₹2.5 lakh per child.

The reduced cost is thanks to pharmaceutical compounding conducted in the Netherlands. Transvaal Pharmacy in The Hague prepared the compounded formulation, making the essential drug accessible. This initiative was spearheaded by Hyderabad-based paediatrician Dr. Sivaranjani Santosh and Access to Medicines India.

The medicine was previously prohibitively expensive for most Indian families. Dr. Sivaranjani initiated efforts after a patient's mother struggled to afford monthly supplies. Social media appeals drew attention, leading to the Pharmaceutical Accountability Foundation (PAF) exploring compounding options.

Funding for the treatment was a collaborative effort. Dr. Sivaranjani raised approximately ₹6.09 lakh in India, while PAF committed to raising the remaining €8,600 (approximately ₹9.13 lakh) in the Netherlands. The first batch of the medicine will be handed over with necessary import permissions for the seven children.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

Read more news on

Property Code: 5571